ReviewAmerican journal of clinical and experimental urology2014
MicroRNAs as predictive biomarkers and therapeutic targets in prostate cancer.
Review in American journal of clinical and experimental urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- The Role of Autophagy in Cancer Evolution and Prognosis, Highlighting Its Role in PCa and Its Interaction with Apoptosis and Epigenetic Regulation by miRNAs.Medical sciences (Basel, Switzerland) · 2026Review
- DNA methylation and miR-92a-3p-mediated repression of HIP1R promotes pancreatic cancer progression by activating the PI3K/AKT pathway.Journal of cellular and molecular medicine · 2023Article
- Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2.Chemical reviews · 2022Review
- Muscarinic Receptors Associated with Cancer.Cancers · 2022Review
- MiR-543/Numb promotes proliferation, metastasis, and stem-like cell traits of prostate cancer cells.American journal of translational research · 2021Article
- A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions.Journal of cheminformatics · 2020Review
- MicroRNA-939 Directly TargetsOncoTargets and therapy · 2020Article
- MicroRNA-200a suppresses prostate cancer progression through BRD4/AR signaling pathway.Cancer medicine · 2019Article
- MicroRNA-30e inhibits adhesion, migration, invasion and cell cycle progression of prostate cancer cells via inhibition of the activation of the MAPK signaling pathway by downregulating CHRM3.International journal of oncology · 2019Article
- MicroRNA-744 promotes prostate cancer progression through aberrantly activating Wnt/β-catenin signaling.Oncotarget · 2017Article
- A survey of current trends in computational drug repositioning.Briefings in bioinformatics · 2016Review
- MiR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition.Oncotarget · 2015Article
- MicroRNA-125a-5p regulates cancer cell proliferation and migration through NAIF1 in prostate carcinoma.OncoTargets and therapy · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostatectomy or irradiation is the most common traditional treatments for localized prostate cancer. In the event of recurrence and/or metastasis, androgen ablation therapy has been the mainstay treatment for many years. Although initially effective, the cancer inevitably recurs as androgen-independent PCa, a disease with limited effective treatments. Enhanced predictive biomarkers are needed at the time of diagnosis to better tailor therapies for patients. MicroRNAs are short nucleotide sequences which can complementary bind to and control gene expression at the post-transcriptional level. Recent studies have demonstrated that many miRNAs are variably expressed in cancers vs. normal tissues, including PCa. In this review, we summarize PCa-specific miRNAs that show potential for their utilization as identifiers of aggressive disease and predictors for risk of recurrence. Additionally, we discuss their potential clinical applications as biomarkers and therapeutic targets.
Indexed as
Identifiers
25374924PMC4219315W343738323What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.